Production (Stage)
Foghorn Therapeutics Inc.
FHTX
$4.32
-$0.22-4.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.50M | 22.60M | 25.52M | 35.19M | 33.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.50M | 22.60M | 25.52M | 35.19M | 33.90M |
| Cost of Revenue | 66.82M | 70.73M | 74.43M | 75.99M | 75.99M |
| Gross Profit | -43.32M | -48.13M | -48.91M | -40.81M | -42.09M |
| SG&A Expenses | 27.89M | 28.36M | 29.03M | 30.37M | 31.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.51M | 122.89M | 127.25M | 130.15M | 136.68M |
| Operating Income | -95.00M | -100.29M | -101.74M | -94.97M | -102.78M |
| Income Before Tax | -80.44M | -86.62M | -89.24M | -83.72M | -89.29M |
| Income Tax Expenses | -- | -- | 1.99M | 2.72M | 3.67M |
| Earnings from Continuing Operations | -80.44 | -86.62 | -91.22 | -86.45 | -92.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.44M | -86.62M | -91.22M | -86.45M | -92.95M |
| EBIT | -95.00M | -100.29M | -101.74M | -94.97M | -102.78M |
| EBITDA | -91.89M | -97.17M | -98.53M | -91.63M | -99.36M |
| EPS Basic | -1.36 | -1.65 | -1.91 | -1.95 | -2.21 |
| Normalized Basic EPS | -0.82 | -1.00 | -1.14 | -1.15 | -1.32 |
| EPS Diluted | -1.36 | -1.65 | -1.91 | -1.95 | -2.21 |
| Normalized Diluted EPS | -0.82 | -1.00 | -1.14 | -1.15 | -1.32 |
| Average Basic Shares Outstanding | 239.90M | 219.48M | 198.84M | 178.27M | 168.51M |
| Average Diluted Shares Outstanding | 239.90M | 219.48M | 198.84M | 178.27M | 168.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |